We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 488 for:    pamela
Previous Study | Return to List | Next Study

PAM50 HER2-enriched Phenotype as a Predictor of Response to Dual HER2 Blockade in HER2-positive Early Breast Cancer (PAMELA)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01973660
Recruitment Status : Active, not recruiting
First Posted : October 31, 2013
Last Update Posted : November 6, 2017
Sponsor:
Collaborator:
Information provided by (Responsible Party):

Study Description
Brief Summary:

Non-randomized, open label, multicentric translational research study in women with untreated invasive breast carcinoma eligible for primary surgery (Stage I-IIIA).

The aim of PAMELA is to test the hypothesis that PAM50 HER2-enriched (HER2-E) subtype better predicts response to neoadjuvant dual anti-HER2 blockade, with or without endocrine therapy, compared to traditional clinical HER2 classification. Furthermore, we posit that characterization of gene expression patterns may identify profiles of those who may be safely spared chemotherapy.


Condition or disease Intervention/treatment Phase
Breast Cancer Drug: Lapatinib Drug: Trastuzumab Drug: Endocrine Therapy Drug: Paclitaxel Phase 2

Detailed Description:

PAMELA is a non-randomized, open label, multicentric translational research study of neoadjuvant dual HER2 blockade therapy without chemotherapy. Although efficacy and safety will be investigated, the primary goal is to identify profiles predictive of clinical benefit from targeted therapy. Eligible patients must be women with untreated primary HER2-overexpressing and/or amplified breast tumors of more than 1 cm in diameter amenable to definitive surgery (stage I-IIIA).

The PAMELA study is designed to test the hypothesis that the PAM50 HER2-E subtype is able to predict clinical response to neoadjuvant dual HER2 blockade with lapatinib and trastuzumab, with or without endocrine therapy, assessed by pathological complete response in the breast (pCRB) rate at the time of surgery, compared to traditional clinical HER2 classification. Furthermore, we posit that characterization of gene expression patterns may identify profiles of those who may be safely spared chemotherapy.

Patients will first undergo screening, tumor measurement, and mandatory collection of core tumor biopsies for central determination of HER2 and HR status. These biopsies will be used to determine gene expression patterns once the patient is included in the study. Patients will be treated with dual HER2 blockade consisting of lapatinib and trastuzumab for a total of 18 weeks. Patients who are HR-positive will also be given endocrine therapy, letrozole or tamoxifen depending on their menopausal status, for the same 18 weeks. If tumor progression is observed by ultrasound (US) at week 6, tumors will be identified as resistant, and paclitaxel will be added to dual HER2 blockade, maintaining trastuzumab at the same original dose and reducing lapatinib dose for safety reasons. In those patients with HR-positive disease, endocrine therapy will be withdrawn in order to avoid its adverse interactions with chemotherapy.

Two weeks after the first administration of study medication, all patients will undergo mandatory repeat tumor tissue acquisition that will be used for secondary endpoint assessment.

Post treatment tissue acquisition will be obtained at the time of surgery from the specimen excised.

US of the breast and axillary lymph nodes will be performed at baseline, Day 14, week 6, and prior to surgery, and will be correlated with pCR. If tumor progression is observed on week 6, the US will be repeated on week 10 to discard the progression continues despite the addition of paclitaxel at neoadjuvant regimen.

Mammography is required at baseline and prior to surgery, but will not be used for the objective response assessment.

Treatment will be given until definitive surgery, clinical signs of disease progression after paclitaxel addition, unacceptable toxicity or withdrawal of patient consent.

Breast surgery will be carried out 1 to 3 weeks after completion of dual HER2 blockade with or without endocrine therapy, and 2 to 3 weeks after completion of paclitaxel plus dual HER2 blockade, should it had been initiated for progressive disease.

Following surgical excision, adjuvant treatment will be as per investigator´s choice and local standards of care outside the scope of this protocol.

End of study is 30 days (±14 days) after surgery with a safety follow-up visit.


Study Design

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 151 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: PAMELA: PAM50 HER2-enriched Phenotype as a Predictor of Early Response to Neoadjuvant Lapatinib Plus Trastuzumab in Stage I to IIIA HER2-positive Breast Cancer
Actual Study Start Date : October 2013
Primary Completion Date : June 2016
Estimated Study Completion Date : December 2017

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Breast Cancer
U.S. FDA Resources

Arms and Interventions

Arm Intervention/treatment
Experimental: Dual HER2 blockade
For a total of 18 weeks, HR-negative patients will be given dual blockade consisting of daily lapatinib at 1000 mg and trastuzumab at a loading dose of 8 mg/kg, followed by 6 mg/kg every 3 weeks.
Drug: Lapatinib
Other Names:
  • Tyverb
  • Tykerb
Drug: Trastuzumab
Other Names:
  • Herceptin
  • Herclon
Drug: Paclitaxel
Only administrated if tumor progression is observed by US on week 6
Other Names:
  • Abraxane
  • Taxol
Experimental: Dual HER2 blockade plus endocrine therapy
For a total of 18 weeks, HR-positive patients will be given letrozole (2.5 mg daily) or tamoxifen (20 mg daily) with concurrent dual blockade consisting of daily lapatinib at 1000 mg and trastuzumab at a loading dose of 8 mg/kg, followed by 6 mg/kg every 3 weeks.
Drug: Lapatinib
Other Names:
  • Tyverb
  • Tykerb
Drug: Trastuzumab
Other Names:
  • Herceptin
  • Herclon
Drug: Endocrine Therapy
Letrozole or tamoxifen will be prescribed according to patient's menopausal status
Other Names:
  • Letrozol, Letrozole, Devazol, Femara, Galdar, Loxifan
  • Tamoxifen, Tamoxifeno, Nolvadex, Istubal, Valodex
Drug: Paclitaxel
Only administrated if tumor progression is observed by US on week 6
Other Names:
  • Abraxane
  • Taxol


Outcome Measures

Primary Outcome Measures :
  1. pCRB to dual HER2 blockade with lapatinib and trastuzumab in all patients, at the time of surgery, predicted by PAM50 HER2-E subtype [ Time Frame: At the time of surgery ]
    Comparison between the PAM50 HER2-E versus non HER2-E cases to achieve pCRB from dual HER2 blockade with lapatinib and trastuzumab at the time of surgery


Secondary Outcome Measures :
  1. Pathological complete response in the breast and axilla (pCRBL) to dual HER2 blockade with lapatinib and trastuzumab, in all patients, at the time of surgery, predicted by PAM50 HER2-E subtype [ Time Frame: At the time of surgery ]
    Comparison between the PAM50 HER2-E versus non HER2-E cases to achieve pCRBL from dual HER2 blockade with lapatinib and trastuzumab at the time of surgery

  2. Residual cancer burden in the breast (RCB) to dual HER2 blockade with lapatinib and trastuzumab, in all patients, at the time of surgery, predicted by PAM50 HER2-E subtype [ Time Frame: At the time of surgery ]
    Correlation between PAM50 HER2-E cases and RCB status (0-I versus II-III) after dual HER2 blockade with lapatinib and trastuzumab at the time of surgery

  3. Changes in the percentage of Ki67-positive cells in PAM50 non-Luminal A/B (combined) subtypes [ Time Frame: Day 14 ]
    Comparison of the changes in the percentage of Ki67-positive cells in Luminal versus non-Luminal subtypes after 14 days of dual HER2 blockade plus endocrine therapy

  4. Gene expression variations in all patients, in HR-negative and in HR-positive patients [ Time Frame: Day 14 ]
    Compare significant changes in gene expression from baseline to Day 14 in the entire study population and separately, in the HR-negative and HR-positive patients

  5. Correlation between PAM50 HER2-E centroid, as a continuous variable, and pCR and/or RCB in the breast to dual HER2 blockade with lapatinib and trastuzumab at the time of surgery [ Time Frame: At the time of surgery ]
  6. Identification of additional gene expression signatures beyond the PAM50 subtypes that predict pCR and/or RCB to dual HER2 blockade with lapatinib and trastuzumab at the time of surgery [ Time Frame: At the time of surgery ]
    In all patients and in those with HR-positive and HR-negative disease

  7. PAM50 risk of relapse (ROR) score and its ability to predict pCR and/or RCB in the breast to dual HER2 blockade with lapatinib and trastuzumab at the time of surgery in all patients and in those with HR-positive and HR-negative disease [ Time Frame: At the time of surgery ]
    Correlation between the PAM50 ROR and pCR and/or RCB after dual HER2 blockade with lapatinib and trastuzumab at the time of surgery

  8. PAM50 HER-2 subtype (PAM50 HER2-E signature) ability as a continuous variable to predict pCRB to dual HER2 blockade at the time of surgery in patients with HR-positive disease and in patients with HR-negative disease [ Time Frame: At the time of surgery ]
  9. Changes in gene expression from day 0 to day 14, after dual HER2 blockade, that predict pCRB in all patients and in those with HR-positive and HR-negative disease [ Time Frame: Day 14 ]
    Identification of gene expression changes that correlate with pCRB or RCB after dual HER2 blockade treatment

  10. Frequency of adverse events (AE) when lapatinib plus trastuzumab, with or without endocrine therapy, is administered in the neoadjuvant setting [ Time Frame: 30 days (+/-14 days) after the surgery ]

    Frequency of adverse events (AE)(assessed by CTCAE v.4.03), including the following parameters:

    • All reported AEs and serious AEs
    • Neutropenia Grade 3/4
    • Febrile neutropenia Grade 3/4
    • Neuropathy Grade 3/4
    • Myalgia/arthralgia
    • Cardiotoxicity (Grade 3/4 or NYHA Class III or IV)
    • Frequency of dose reductions and dose delays due to treatment toxicity


Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Written informed consent prior to beginning specific protocol procedures
  • Untreated invasive breast carcinoma eligible for primary definitive surgery (stage I-IIIA)
  • Histologically confirmed invasive breast carcinoma, with all of the following characteristics: primary tumor ≥1 cm in largest diameter, cN0-2, No evidence of distant metastasis (M0)
  • HER2-positive invasive breast cancer by central assessment, defined by ASCO/CAP guidelines
  • Female patients
  • Age ≥18 years
  • ECOG performance status of 0 or 1
  • Adequate organ function defined as: Absolute neutrophil count (ANC) ≥1.5 × 109/L, Hemoglobin (Hgb) ≥10 g/dL, Platelets >100 000/mm3, Creatinine ≤1.6 mg/dL, ALT and AST ≤2.5 × ULN, Alkaline phosphatase ≤5 ULN, Total bilirubin ≤1.5 mg/dL, Baseline LVEF ≥50% measured by echocardiography (ECHO) or Multiple Gate Acquisition (MUGA) scan
  • Negative β-HCG pregnancy test (serum) for premenopausal women of reproductive capacity (those who are biologically capable of having children) and for women less than 12 months after the menopause. All subjects who are biologically capable of having children must agree and commit to the use of a reliable method of birth control from 2 weeks before administration of the first dose of investigational product until 28 days after last dose of investigational product
  • Absence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule
  • In the case of multifocal tumor (defined as the presence of two or more tumor foci in the same quadrant of the breast), the largest lesion must be ≥ 1 cm, and "target lesion" must be designated for all subsequent tumor assessments. In all tumor foci should be documented HER2 status as positive
  • Availability of enough tumor sample or possibility to take a new biopsy for PAM50 analysis

Exclusion Criteria:

  • Stage III inoperable breast cancer or known metastatic disease
  • Patients for whom upfront chemotherapy including taxanes and anthracyclines is clinically judged appropriate as optimal neoadjuvant treatment
  • Prior chemotherapy, radiotherapy or surgery for invasive breast cancer, other than excision of tumor in the contralateral breast, and provided that the patient did not previously receive adjuvant radiotherapy or chemotherapy
  • Subjects with a concurrently active second malignancy, other than adequately treated non-melanoma skin cancers, in situ melanoma or in situ cervical cancer. Subjects with other non-mammary malignancies must have been disease-free for at least 5 years
  • Known or suspected hypersensitivity reaction to any investigational or therapeutic compound or their incorporated substances
  • Concurrent congestive heart failure or LVEF <50%
  • Clinically significant (i.e. active) cardiovascular disease, including cerebrovascular accident (<6 months before enrollment), unstable angina pectoris, myocardial infarction ≤6 months before enrollment, uncontrolled hypertension (systolic >150 mmHg and/or diastolic >100 mmHg) or high-risk uncontrolled arrhythmias
  • Uncontrolled diabetes mellitus, active peptic ulcer disease or uncontrolled epilepsy
  • Active uncontrolled infection at the time of enrollment
  • History of significant comorbidities that, in the judgment of the investigator, may interfere with the conduction of the study, the evaluation of response, or with informed consent
  • Use of any investigational agent or participation in another therapeutic clinical trial concurrently or in the previous 30 days before the enrollment
  • Patients who are pregnant or breast-feeding
  • Women of child-bearing potential who are unable or unwilling to use contraceptive measures
  • Inability or unwillingness to abide by the study protocol or cooperate fully with the investigator
  • Malabsorption syndrome, disease significantly affecting gastrointestinal function, or resection of the stomach or small bowel. Subjects with ulcerative colitis are also excluded
  • Concurrent neoadjuvant cancer therapy (chemotherapy, radiation therapy, immunotherapy, biologic therapy other than the trial therapies)
  • Concomitant use of CYP3A4 inhibitors or inducers
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01973660


Locations
Spain
Hospital de Torrevieja
Torrevieja, Alicante, Spain
Institut Català d'Oncologia Hospitalet
Hospitalet de Llobregat, Barcelona, Spain
Hospital Mutua de Terrassa
Terrassa, Barcelona, Spain
Consorcio Hospitalario Provincial de Castellón
Castelló de la Plana, Castellón, Spain
Hospital Clínico Universitario de Santiago de Compostela
Santiago de Compostela, Galicia, Spain
Hospital Son Llàtzer
Palma de Mallorca, Islas Baleares, Spain
Hospital Universitario Son Espases
Palma de Mallorca, Islas Baleares, Spain
Hospital Universitario de Fuenlabrada
Fuenlabrada, Madrid, Spain
Hospital Universitario Virgen de la Arrixaca
El Palmar, Murcia, Spain
Hospital Universitario Sant Joan de Reus
Reus, Tarragona, Spain
Hospital Luis Alcanyís de Xàtiva
Xàtiva, Valencia, Spain, 46800
Hospital Universitario Infanta Cristina
Badajoz, Spain, 06071
Vall d'Hebron University Hospital
Barcelona, Spain, 08035
Hospital Clínic de Barcelona
Barcelona, Spain
Instituto Dexeus
Barcelona, Spain
Hospital San Pedro de Alcántara
Cáceres, Spain, 10003
Hospital Universitario Arnau de Vilanova de Lleida
Lleida, Spain
Hospital Universitario 12 de Octubre
Madrid, Spain, 28041
Hospital Clínico San Carlos
Madrid, Spain
Hospital Universitario Ramón y Cajal
Madrid, Spain
Hospital Clínico Universitario de Valencia
Valencia, Spain
Hospital Universitario Arnau de Vilanova de Valencia
Valencia, Spain
Sponsors and Collaborators
SOLTI Breast Cancer Research Group
Novartis
Investigators
Study Chair: Antonio Llombart, MD, PhD Hospital Arnau de Vilanova de Valencia
Study Chair: Aleix Prat, MD, PhD Vall d'Hebron Institute of Oncology (VHIO)
Study Chair: Javier Cortés, MD, PhD Vall d'Hebron University Hospital
More Information

Additional Information:
Publications:

Responsible Party: SOLTI Breast Cancer Research Group
ClinicalTrials.gov Identifier: NCT01973660     History of Changes
Other Study ID Numbers: SOLTI-1114
2013-001036-22 ( EudraCT Number )
First Posted: October 31, 2013    Key Record Dates
Last Update Posted: November 6, 2017
Last Verified: October 2017

Keywords provided by SOLTI Breast Cancer Research Group:
Human Epidermal Growth Factor Receptor 2
HER2
HER2 positive
PAM50
lapatinib
trastuzumab
dual HER2 blockade
neoadjuvant

Additional relevant MeSH terms:
Breast Neoplasms
Neoplasms by Site
Neoplasms
Breast Diseases
Skin Diseases
Letrozole
Lapatinib
Trastuzumab
Tamoxifen
Antineoplastic Agents
Aromatase Inhibitors
Steroid Synthesis Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Estrogen Antagonists
Hormone Antagonists
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Protein Kinase Inhibitors
Antineoplastic Agents, Hormonal
Selective Estrogen Receptor Modulators
Estrogen Receptor Modulators
Bone Density Conservation Agents